Enlighten (Chronic Rhinosinusitis Program)

2022: Announcement of a program for the treatment of chronic rhinosinusitis

On September 8, 2022, Lyra Therapeutics announced the enrollment of the first patient in a Phase 3 clinical trial of the Enlighten II program.

Enlighten II suggests the use of the drug LYR-210 the company among adult patients with chronic rhinosinusitis (CRS). Lyra's patented XTreo platform implements LYR-210.

A program has been created to treat chronic rhinosinusitis

Enlighten II is the second Phase 3 trial in the core clinical program for LYR-210. Lyra started Enlighten I in January 2022. Both trials will involve patients with no surgery for CRS USA To Europe in and to support the company's application for. FDA

We are looking at the Enlighten program with enthusiasm: both Phase 3 trials are already actively recruiting patients, "said Maria Palasis, President and CEO of Lyra Therapeutics. LYR-210 is the first CRS candidate drug designed to provide six months of continuous treatment through a single dose, and we are focused on the opportunity to offer a new standard of care to the millions of CRS patients suffering from the disease.

Enlighten's program includes a total of 360 adult patients with CRS. The Enlighten II program will include about 180 patients with CRS who have not been able to undergo medical treatment and have not undergone sinus surgery before. The primary endpoint is the change from baseline in the composite score of the three main symptoms of CRS (i.e., nasal blockage, nasal discharge, and facial pain) at Week 24.

I'm very pleased that the first patient was enrolled at our center in this important study, "said Adil Fatakia of Tandem Clinical Research. My fellow researchers elsewhere in the US and around the world are looking forward to enrolling patients in this study to gather the necessary data to help present this program for approval.[1]

Notes

Шаблон:Remarks